- Home
- LRMR vs AVR Comparison
LRMR vs AVR Comparison
Compare LRMR & AVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- AVR
- Stock Information
- Founded
- LRMR N/A
- AVR 1999
- Country
- LRMR United States
- AVR Australia
- Employees
- LRMR N/A
- AVR N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- AVR
- Sector
- LRMR Health Care
- AVR
- Exchange
- LRMR Nasdaq
- AVR NYSE
- Market Cap
- LRMR 191.4M
- AVR 162.1M
- IPO Year
- LRMR N/A
- AVR 2024
- Fundamental
- Price
- LRMR $3.09
- AVR $3.80
- Analyst Decision
- LRMR Strong Buy
- AVR Strong Buy
- Analyst Count
- LRMR 7
- AVR 4
- Target Price
- LRMR $17.86
- AVR $16.50
- AVG Volume (30 Days)
- LRMR 1.4M
- AVR 304.0K
- Earning Date
- LRMR 08-06-2025
- AVR 08-16-2025
- Dividend Yield
- LRMR N/A
- AVR N/A
- EPS Growth
- LRMR N/A
- AVR N/A
- EPS
- LRMR N/A
- AVR N/A
- Revenue
- LRMR N/A
- AVR $2,493,000.00
- Revenue This Year
- LRMR N/A
- AVR $25.79
- Revenue Next Year
- LRMR N/A
- AVR $211.91
- P/E Ratio
- LRMR N/A
- AVR N/A
- Revenue Growth
- LRMR N/A
- AVR N/A
- 52 Week Low
- LRMR $1.61
- AVR $2.34
- 52 Week High
- LRMR $11.20
- AVR $8.79
- Technical
- Relative Strength Index (RSI)
- LRMR 60.78
- AVR N/A
- Support Level
- LRMR $2.81
- AVR N/A
- Resistance Level
- LRMR $3.19
- AVR N/A
- Average True Range (ATR)
- LRMR 0.30
- AVR 0.00
- MACD
- LRMR 0.01
- AVR 0.00
- Stochastic Oscillator
- LRMR 82.43
- AVR 0.00
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.